• Je něco špatně v tomto záznamu ?

Evidence of 68Ga-DOTA-NT-20.3 Uptake in Pancreatic Adenocarcinoma AsPC-1 Cell Line - in vitro Study

M. Marenco, L. Lodola, MG. Persico, V. Frangipane, A. Facoetti, C. Aprile, M. Hodolič,

. 2018 ; 19 (9) : 754-759.

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012425

BACKGROUND: Neurotensin receptors are overexpressed in several cancer types including pancreatic ductal adenocarcinoma. Three NTR subtypes have been cloned: NTR-1, NTR-2 and NTR-3. The most expressed NTR-1 is not present in normal pancreatic tissue and has a low expression in chronic pancreatitis. OBJECTIVE: Objective of this study was to test in vitro affinity of the new 68Ga labelled neurotensin analogue DOTA-NT-20.3 (fragment 6-13, Ac-Lys(DOTA)-Pro-Arg(N-CH3)-Arg-Pro-Tyr-Tle-Leu) on the human pancreatic ductal adenocarcinoma cell line AsPC-1. METHOD: For the preparation of 68Ga-DOTA-NT-20.3, 68GaCl3 solution (eluted from 68Ge/68Ga generator) and 50 μg of precursor (Iason, Graz, Austria) water dissolved were used in an automatic synthesis module. The labeled compound was added to cell culture flask and incubated at 37°C. At various time points after tracer addition up to 80min, cells were recovered, rinsed and counted for radioactivity. Results were expressed as percent binding normalized to 200000 cells and affinity parameters were calculated. RESULTS: Labeling yield was ≥98 %. The molar ratio between labelled and total peptide was about 1/400. AsPC-1 cell line showed rapid uptake of the tracer including surface and internalized binding, tending to a plateau phase 80 min after tracer addition (11%/200.000 cells). The Kd (7.335 pmol) and Bmax (90.52 kBq) value indicated high tracer affinity for AsPC-1cell line especially if compared with the literature data regarding other malignancies (e.g. colonic cancer cell line). Binding sites were 1.09x106 sites per cell. CONCLUSION: New tracer 68Ga-DOTA-NT-20.3 can be a suitable candidate for the clinical use in patients with pancreatic ductal adenocarcinoma.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012425
003      
CZ-PrNML
005      
20190411101643.0
007      
ta
008      
190405s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.2174/1389201019666180829152314 $2 doi
035    __
$a (PubMed)30160211
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Marenco, Manuela $u Nuclear Medicine Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
245    10
$a Evidence of 68Ga-DOTA-NT-20.3 Uptake in Pancreatic Adenocarcinoma AsPC-1 Cell Line - in vitro Study / $c M. Marenco, L. Lodola, MG. Persico, V. Frangipane, A. Facoetti, C. Aprile, M. Hodolič,
520    9_
$a BACKGROUND: Neurotensin receptors are overexpressed in several cancer types including pancreatic ductal adenocarcinoma. Three NTR subtypes have been cloned: NTR-1, NTR-2 and NTR-3. The most expressed NTR-1 is not present in normal pancreatic tissue and has a low expression in chronic pancreatitis. OBJECTIVE: Objective of this study was to test in vitro affinity of the new 68Ga labelled neurotensin analogue DOTA-NT-20.3 (fragment 6-13, Ac-Lys(DOTA)-Pro-Arg(N-CH3)-Arg-Pro-Tyr-Tle-Leu) on the human pancreatic ductal adenocarcinoma cell line AsPC-1. METHOD: For the preparation of 68Ga-DOTA-NT-20.3, 68GaCl3 solution (eluted from 68Ge/68Ga generator) and 50 μg of precursor (Iason, Graz, Austria) water dissolved were used in an automatic synthesis module. The labeled compound was added to cell culture flask and incubated at 37°C. At various time points after tracer addition up to 80min, cells were recovered, rinsed and counted for radioactivity. Results were expressed as percent binding normalized to 200000 cells and affinity parameters were calculated. RESULTS: Labeling yield was ≥98 %. The molar ratio between labelled and total peptide was about 1/400. AsPC-1 cell line showed rapid uptake of the tracer including surface and internalized binding, tending to a plateau phase 80 min after tracer addition (11%/200.000 cells). The Kd (7.335 pmol) and Bmax (90.52 kBq) value indicated high tracer affinity for AsPC-1cell line especially if compared with the literature data regarding other malignancies (e.g. colonic cancer cell line). Binding sites were 1.09x106 sites per cell. CONCLUSION: New tracer 68Ga-DOTA-NT-20.3 can be a suitable candidate for the clinical use in patients with pancreatic ductal adenocarcinoma.
650    _2
$a adenokarcinom $x metabolismus $x patologie $7 D000230
650    _2
$a zvířata $7 D000818
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a radioizotopy galia $x chemie $x metabolismus $7 D005710
650    _2
$a heterocyklické sloučeniny monocyklické $x chemie $x metabolismus $7 D006573
650    _2
$a lidé $7 D006801
650    _2
$a neurotensin $x agonisté $x chemie $x metabolismus $7 D009496
650    _2
$a nádory slinivky břišní $x metabolismus $x patologie $7 D010190
650    _2
$a peptidové fragmenty $x chemie $x metabolismus $7 D010446
650    _2
$a receptory neurotensinu $x metabolismus $7 D018028
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lodola, Lorenzo $u Nuclear Medicine Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
700    1_
$a Persico, Marco G $u Nuclear Medicine Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. University School for Advanced Studies IUSS, Pavia, Italy.
700    1_
$a Frangipane, Vanessa $u Nuclear Medicine Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. Respiratory Diseases Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy.
700    1_
$a Facoetti, Angelica $u CNAO Foundation, Pavia, Italy.
700    1_
$a Aprile, Carlo $u Nuclear Medicine Unit, IRCCS Policlinico San Matteo Foundation, Pavia, Italy. CNAO Foundation, Pavia, Italy.
700    1_
$a Hodolič, Marina $u Nuclear Medicine Research Department IASON, Graz, Austria. Department of Nuclear Medicine, Faculty of Medicine and Dentistry, Palacký University, Olomouc, Czech Republic.
773    0_
$w MED00007892 $t Current pharmaceutical biotechnology $x 1873-4316 $g Roč. 19, č. 9 (2018), s. 754-759
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30160211 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190411101641 $b ABA008
999    __
$a ok $b bmc $g 1391735 $s 1050730
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 19 $c 9 $d 754-759 $i 1873-4316 $m Current pharmaceutical biotechnology $n Curr Pharm Biotechnol $x MED00007892
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace